The potential of targeting lipid metabolizing cytochrome P450 enzymes for lung cancer treatment

Date

Nov 29, 2023

Time

1:00 PM - 2:00 PM

Speaker

Simone Brixius-Anderko, Ph.D.

Affiliation

University of Pittsburgh School of Pharmacy, Center for Pharmacogenetics, Pittsburgh, USA

Language

en

Main Topic

Biologie

Host

Membrane Reconstitution Club / Theresia Gutmann

Description

Lung cancer is the leading cause for cancer-related deaths worldwide with limited treatment options. Thus, new orthogonal treatment options are urgently needed. The cytochrome P450 4F11 (CYP4F11) is heavily upregulated in lung cancer patients. CYP4F11 catalyzes the w-hydroxylation of arachidonic acid yielding 20-hydroxyeicosatetraenoic acid (20-HETE). 20-HETE is a potent lipid mediator and regulates blood pressure and angiogenesis in healthy individuals. In cancer, 20-HETE signaling leads to cell proliferation and migration and tumor angiogenesis. The Brixius lab has recently shown that a transient knockdown of CYP4F11 in lung cancer cell lines dramatically attenuates cell proliferation and migration, thus, demonstrating the high potential of CYP4F11 as drug target. We use a combination of cell biology, biochemistry, and X-ray protein crystallography to reveal structure and function of CYP4F11 and accelerate its use as lung cancer drug target for transformative therapeutics.

Last modified: Nov 30, 2023, 7:36:01 AM